secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001558370-25-004070
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences reports FY 2024 net income $2.8M; Phase 1b PRECISE-AD enrolling
--------------------------------------------------------------------------------

- Cash $13.3M at Dec 31, 2024; PIPE financing provided $30.3M upfront with potential $92.4M from warrants.
- R&D expenses $10.6M (up 34% YoY) driven by Phase 1a/1b clinical costs; net income of $2.8M vs loss of $13.2M in 2023.
- Gain on change in fair value of warrant liabilities of $22.6M drove net income; operating loss remains.
- Phase 1b PRECISE-AD trial (NCT06750432) dosed multiple patients; plans ~100 subjects at 22 US sites.
- Interim results from PRECISE-AD expected 1H 2026, topline results by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/0001558370-25-004070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer